SIGA Technologies - US stockpiles front and center in Q1 and FY23
SIGA’s Q123 results were largely driven by US TPOXX deliveries under existing contracts. Q123 product revenues of $5.7m ($7.3m in Q122) were...
16 Views
SIGA Technologies - Solid results marked by revenue diversification
SIGA’s FY22 results highlighted underlying revenue diversification and clinical progression during the year. Results were broadly in line with our...
230 Views
SIGA Technologies - Solid Q322, underpinned by international traction
SIGA reported robust Q322 results, with sales momentum driven by international deliveries of oral TPOXX as governments expedited stockpiling to...
248 Views
SIGA Technologies - TPOXX trials launched in treating monkeypox
SIGA Technologies has shared an update on the progress of three clinical trials assessing TPOXX for treating monkeypox. Recently, three randomized,...
669 Views
SIGA Technologies - Second contract win from the US DoD in 2022
SIGA Technologies has announced a second procurement contract worth up to $10.7m from the US Department of Defense (DoD) for the procurement of...
670 Views